Background/aims: We have shown that continuous intra-arterial combination chemotherapy (IACC) might be more effective for advanced HCC (aHCC) in patients with HCV-related (C-LC) or alcoholic (A-LC) liver cirrhosis (LC) patients than in patients with HBV-related LC (B-LC). This study retrospectively assesses the difference of etiology on host immunity in LC patients with aHCC treated by IACC.
Methodology: Forty-seven adult LC patients with aHCC were treated by IACC between 2005 and 2008, with inoperable tumors according to CT findings. IACC (LV at 12 mg/hr, CDDP at 10 mg/hr, and 5-FU at 250 mg/22 hr) was delivered via the proper hepatic artery every 5 days for 4 weeks using a catheter connected to a subcutaneously implanted drug delivery system. The control group comprised 13 healthy volunteers.
Results: Twelve of the 47 patients with aHCC had B-LC, 27 had C-LC, and 8 had A-LC. In the B-LC group, 1 out of 12 patients had a Japan Integrated Staging (JIS) score of 2, 4 had a JIS score of 3, 7 had a JIS score of 4, and no patients had a JIS score of 5, while the respective numbers were 6, 9, 10 and 2 in the C-LC group, and 1, 1, 5 and 1 in the A-LC group. The response rates were 37.0%, 37.5% and 8.3% in the C-LC, A-LC and B-LC group, respectively. In the C-LC group, the percentage of Th1 cells before and after chemotherapy was significantly higher than in the control group. In the B-LC group, the percentage of Th2 cells after chemotherapy was significantly higher than that in the control group. However, there were no significant differences of Th1 and Th2 cells between the A-LC group and the control group.
Conclusions: These results indicate that IACC was more effective for aHCC in A-LC patients with normal Th1/Th2 balance and in C-LC patients without Th2 dominance than in B-LC patients who showed Th2 dominance after chemotherapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5754/hge10598 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dupilumab treatment reduces caregiver-reported skin pain in patients with moderate-to-severe atopic dermatitis aged 6 months to 5 years.
Front Pediatr
September 2024
Sanofi, Cambridge, MA, United States.
Article Synopsis
- Moderate-to-severe atopic dermatitis (AD) significantly affects the quality of life for young children and their caregivers, with skin pain being a major symptom.
- In a study involving 162 children aged 6 months to 5 years, those treated with dupilumab showed a greater reduction in skin pain compared to the placebo group after 16 weeks.
- The results indicate that dupilumab treatment leads to rapid and significant improvements in skin pain, benefiting both the overall patient population and specific subgroups struggling with more severe symptoms.
Abrocitinib may improve itch and quality of life in patients with itch-dominant atopic dermatitis.
Skin Health Dis
August 2024
Chicago Medical School, Rosalind Franklin University of Medicine and Science North Chicago Illinois USA.
Article Synopsis
- * Data was pooled from multiple clinical trials where patients received abrocitinib either alone or with topical treatments, measuring outcomes like itch severity and overall quality of life improvements.
- * Results indicated that patients treated with abrocitinib saw significant reductions in itch and better overall skin assessments compared to those on placebo, with many achieving marked improvements by Week 12 of treatment.
Pulmonary function in patients with idiopathic scoliosis 40 years after diagnosis.
Spine J
November 2024
Department of Orthopedic Surgery, Spine Unit, Rigshospitalet, Copenhagen, Denmark.
Background Context: Pulmonary function in patients with scoliosis has been a topic of concern, with some reports of markedly decreased ventilatory function leading to disability and increased mortality in patients with severe scoliosis. Only limited data is available concerning pulmonary function in adult patients with scoliosis.
Purpose: To report the long-term pulmonary function (PF) in patients diagnosed with idiopathic scoliosis (IS) compared with an age-matched population using extended pulmonary function testing (EPFT).
Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials.
Lancet
August 2024
Global Research and Development, Galderma, Zug, Switzerland. Electronic address:
Article Synopsis
- * The trials involved adult and adolescent participants with moderate-to-severe atopic dermatitis and were conducted across 22 countries, comparing the effects of 30 mg of nemolizumab versus a placebo alongside topical corticosteroids.
- * Key measures included improvements in skin clear-up (IGA score) and eczema severity (EASI-75), as well as pruritus and sleep disturbances at various intervals, with outcomes assessed through masked evaluators.
The Development of New Scoring System to Define the Presence of Instability and the Need of Fusion in Degenerative Lumbar Spinal Stenosis - Jakarta Instability Score.
Global Spine J
January 2025
Department of Radiology, Faculty of Medicine Universitas Indonesia, Dr. Cipto Mangunkusumo National Central Public Hospital, Jakarta, Indonesia.
Study Design: Systematic review, expert opinion and Delphi technique, and validity and reliability studies.
Objective: We developed Jakarta Instability Score (JIS) to identify spinal instability and the need of fusion in degenerative lumbar spinal stenosis (LSS).
Methods: This study consisted of systematic review to find predictors of spinal instability, expert opinion and modified Delphi technique to develop JIS, and validity and reliability studies of the newly developed JIS.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!